Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Revenue (2016 - 2025)

Karyopharm Therapeutics' Revenue history spans 14 years, with the latest figure at $34.1 million for Q4 2025.

  • For Q4 2025, Revenue rose 11.58% year-over-year to $34.1 million; the TTM value through Dec 2025 reached $146.1 million, up 0.57%, while the annual FY2025 figure was $146.1 million, 0.57% up from the prior year.
  • Revenue reached $34.1 million in Q4 2025 per KPTI's latest filing, down from $44.0 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $126.3 million in Q4 2021 to a low of $22.6 million in Q2 2021.
  • Average Revenue over 5 years is $40.2 million, with a median of $36.9 million recorded in 2022.
  • Peak YoY movement for Revenue: surged 259.74% in 2021, then tumbled 73.41% in 2022.
  • A 5-year view of Revenue shows it stood at $126.3 million in 2021, then crashed by 73.41% to $33.6 million in 2022, then increased by 0.5% to $33.7 million in 2023, then dropped by 9.5% to $30.5 million in 2024, then increased by 11.58% to $34.1 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Revenue are $34.1 million (Q4 2025), $44.0 million (Q3 2025), and $37.9 million (Q2 2025).